GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Reneo Pharmaceuticals
Reneo Pharma is a biotech company developing drugs to treat rare genetic diseases. Its stock price is driven by news of clinical trials. The chart reflects the binary risks and hopes associated with new drug development.
Share prices of companies in the market segment - Specialized pharma
Reneo Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare genetic mitochondrial diseases. We classify it as a "Specialty Pharma" company. The chart below shows how investors value companies working in the orphan disease field.
Broad Market Index - GURU.Markets
Reneo Pharmaceuticals is a biopharmaceutical company developing treatments for rare genetic mitochondrial diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Reneo shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
RPHM - Daily change in the company's share price Reneo Pharmaceuticals
For Reneo Pharmaceuticals, Inc., a company developing drugs to treat rare diseases, daily volatility reflects sensitivity to clinical trial data. This metric is an important element in risk assessment.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Reneo Pharmaceuticals is a biopharmaceutical company developing treatments for rare genetic mitochondrial diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing RPHM stock performance.
Daily change in the price of a broad market stock, index - GURU.Markets
Reneo Pharmaceuticals is a pharmaceutical company developing new drugs. Its shares, like many in the sector, are volatile and react to news about clinical trials. These scientifically driven movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Reneo Pharmaceuticals
Reneo Pharmaceuticals' year-to-date performance is a story about its drug development for rare genetic diseases. Its 12-month market cap is entirely dependent on clinical trial data. The success of its lead candidate, which aims to enhance energy metabolism, could offer new hope for patients.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Reneo, a late-stage biotech company, develops drugs for rare diseases. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Reneo Pharmaceuticals is a classic biotech company whose fate is decided in the lab. Its year-over-year performance compared to the S&P 500 tells a story not about economics, but about investors' faith in the success of its rare disease drugs. Any piece of news could change everything.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Reneo Pharmaceuticals
Reneo is a biopharmaceutical company. Its monthly performance is typical for the sector: it depends on progress in its scientific developments and clinical programs. News of the results of its rare disease drug trials are the main drivers.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
Reneo Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare genetic diseases associated with impaired cellular energy metabolism. The chart below illustrates the overall dynamics in the specialty pharmaceutical sector, where a focus on orphan diseases is opening up new opportunities.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks often live in a world of their own, where clinical trial news trumps overall market trends. The chart below shows the pulse of the broader market. Does Reneo Pharmaceuticals move in sync with it, or do its R&D developments create a completely independent story?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Reneo Pharmaceuticals
Reneo, a biopharmaceutical company, shares reflect the search for cures for rare genetic diseases on a weekly basis. Share prices respond to data from clinical trials of its drugs aimed at improving cellular metabolism.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Reneo Pharmaceuticals develops drugs to treat rare genetic mitochondrial diseases. This chart helps separate its own news-driven dynamics from the broader pharma sector, showing how the market views its chances of success in this complex field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Reneo Pharmaceuticals is a biopharmaceutical company. Its success depends on the results of clinical trials. The chart will help you understand: does Reneo live in its own world of scientific news, or are the overall market conditions and risk appetite in the biotech sector actually influencing its stock price?
Market capitalization of the company, segment and market as a whole
RPHM - Market capitalization of the company Reneo Pharmaceuticals
Reneo's market capitalization tells the story of a biotech company developing drugs to treat rare genetic diseases related to metabolism. Its volatile price chart reflects investors' assessment of clinical trial data. Its trajectory is a narrative of hope for new treatments for patients with disabilities.
RPHM - Share of the company's market capitalization Reneo Pharmaceuticals within the market segment - Specialized pharma
Reneo Pharmaceuticals is a biotech company specializing in rare genetic diseases. Its share of its segment's market capitalization reflects expectations for the success of its clinical programs. The chart shows how development news impacts its market share and investor confidence.
Market capitalization of the market segment - Specialized pharma
Reneo Pharmaceuticals is a clinical-stage biotech company focused on rare genetic diseases. The chart below shows the overall market capitalization of this sector. Its dynamics are a roller coaster, reflecting investor hopes for a scientific breakthrough and the development of a new, effective drug.
Market capitalization of all companies included in a broad market index - GURU.Markets
Reneo Pharmaceuticals is a biotech company developing drugs to treat rare genetic diseases related to metabolism. Its market cap reflects the hope of patients and investors' faith in its science. Its volatility on the overall chart is typical of biotech, where clinical trial data is crucial.
Book value capitalization of the company, segment and market as a whole
RPHM - Book value capitalization of the company Reneo Pharmaceuticals
Reneo Pharmaceuticals' book value is the capital invested in developing drugs for rare genetic diseases associated with energy metabolism disorders. This is a tangible, scientific foundation aimed at helping patients with limited treatment options. How has this biotech asset changed? The chart below shows its dynamics.
RPHM - Share of the company's book capitalization Reneo Pharmaceuticals within the market segment - Specialized pharma
Reneo Pharmaceuticals develops drugs to treat rare genetic diseases, which requires R&D laboratories. The chart shows the share of these science-intensive tangible assets, reflecting the physical foundation of its scientific activities.
Market segment balance sheet capitalization - Specialized pharma
Reneo, a clinical-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
Reneo Pharma's balance sheet isn't its manufacturing plants, but its intellectual property for a drug for treating rare genetic diseases related to metabolism. The company's assets are the capitalized results of its R&D. The chart below shows how this rare disease-focused biotech company breaks down in terms of assets.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Reneo Pharmaceuticals
Reneo Pharmaceuticals develops drugs to treat rare genetic diseases. Its balance sheet reflects R&D expenses. Its market capitalization reflects the hopes for approval of its life-changing drugs. The chart reflects the high risks and potentially enormous returns of investing in orphan drugs.
Market to book capitalization ratio in a market segment - Specialized pharma
Reneo Pharmaceuticals is a clinical-stage biotech company developing drugs to treat rare genetic diseases. Its market valuation chart reflects the potential of its developments and progress in clinical trials, attracting speculative interest.
Market to book capitalization ratio for the market as a whole
Reneo Pharmaceuticals is a company developing drugs to treat rare diseases. Its market valuation reflects investors' bets on the future success of its developments. This chart provides context for understanding how high expectations are in the biotech sector compared to the market average.
Debts of the company, segment and market as a whole
RPHM - Company debts Reneo Pharmaceuticals
Reneo Pharmaceuticals, a clinical-stage biotech developing drugs to treat rare genetic diseases, uses capital to fund its research. This chart shows how the company manages its resources to advance its scientific developments through the complex and costly clinical trials process.
Market segment debts - Specialized pharma
Reneo Pharmaceuticals is a clinical-stage biotech company focused on rare genetic diseases. Financing for such companies relies almost entirely on equity, as the lack of revenue makes debt extremely risky. This chart likely reflects minimal use of leverage.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Reneo Pharmaceuticals
Reneo Pharmaceuticals is a clinical-stage biotech company focused on treating rare genetic diseases. Its operations are entirely funded by investors. This chart shows the extent to which the company uses debt to conduct clinical trials, which directly reflects the level of financial risk for shareholders.
Market segment debt to market segment book capitalization - Specialized pharma
Reneo Pharmaceuticals is a clinical-stage biotech company developing drugs to treat rare genetic diseases related to metabolism. The chart shows how aggressively the sector uses debt to fund R&D, providing context for assessing Reneo's financial strategy and risks.
Debt to book value of all companies in the market
Reneo Pharmaceuticals, a clinical-stage biopharmaceutical company developing drugs to treat rare genetic diseases, requires significant funding. This chart, showing the overall market debt burden, provides context. It helps assess how the company's financial strategy is aligned with the high risks and long development cycles of biotech.
P/E of the company, segment and market as a whole
P/E - Reneo Pharmaceuticals
Reneo Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to treat rare genetic mitochondrial diseases. This chart shows how investors rate its scientific focus. The assessment is based on the potential of its drugs to improve cellular energy metabolism.
P/E of the market segment - Specialized pharma
Reneo's focus on treating rare diseases is a high-potential niche. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Reneo is valued based on the potential of its drugs for treating rare genetic diseases, where there is a significant unmet need.
P/E of the market as a whole
Reneo Pharmaceuticals is a biopharmaceutical company specializing in developing treatments for rare genetic diseases. Its valuation is entirely dependent on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, as reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Reneo Pharmaceuticals
For Reneo Pharmaceuticals, a company developing drugs to treat rare genetic diseases, this chart illustrates market expectations for its clinical programs. It reflects investor confidence in the potential of its lead candidate for patients with energy metabolism disorders.
%20P%2FE%20Reneo%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Reneo-Pharmaceuticals&v=1772658262561 "Chart of the company's future (projected) P/E Reneo Pharmaceuticals")
Future (projected) P/E of the market segment - Specialized pharma
Reneo Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to treat rare genetic mitochondrial diseases. This chart shows industry forecasts. This helps assess how the market perceives Reneo's potential to treat diseases where cellular energy function is impaired.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772658262567 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Reneo Pharmaceuticals, Ltd. is a biopharmaceutical company developing drugs to treat rare genetic diseases. The company's valuation is based on the potential of its scientific developments. This overall risk appetite chart shows how willing investors are to fund fundamental research in rare diseases.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772658262577 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Reneo Pharmaceuticals
Reneo Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to treat rare genetic mitochondrial diseases. With no products on the market, its financial results represent losses from R&D. This chart shows the cost of developing drugs for highly complex orphan diseases.
Profit of companies in the market segment - Specialized pharma
Reneo Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare genetic mitochondrial diseases. This chart, which shows profitability in the pharmaceutical sector, demonstrates the importance of drug discovery for orphan diseases. Their research is focused on improving mitochondrial function, which could help patients with severe and debilitating conditions.
Overall market profit
Reneo Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare genetic mitochondrial diseases. This is a niche area with a high unmet need. Success depends on clinical trial results. This total return chart reflects the investment climate important for funding such specialized developments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Reneo Pharmaceuticals
Reneo Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare genetic mitochondrial diseases that cause muscle weakness. This chart represents analyst consensus forecasts for clinical trial success and the potential of their drugs for patients with limited treatment options.
%20profit%20of%20the%20company%20Reneo%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Reneo-Pharmaceuticals&v=1772658262606 "Graph of future (projected) profit of the company Reneo Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Specialized pharma
Reneo Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to treat rare genetic mitochondrial diseases. Its future depends on the success of clinical trials. This biotech chart reflects the general expectations for companies operating in the orphan disease niche.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772658262610 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
Reneo Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare genetic diseases. Its future is determined by the success of clinical trials. The overall economic outlook, reflected in this chart, impacts the investment climate and the availability of capital to continue development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772658262615 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Reneo Pharmaceuticals
Reneo Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare genetic mitochondrial diseases. For a clinical-stage company, this chart is key. It shows how investors assess the potential of its lead candidate, betting on success in an area of high medical need.
P/S market segment - Specialized pharma
Reneo Pharmaceuticals develops drugs to treat rare genetic mitochondrial diseases. The clinical-stage company's valuation is based on the future potential of its targeted therapies. This chart, which displays average biotech valuations, provides context for understanding how the market views Reneo's scientific approach and development pipeline.
P/S of the market as a whole
Reneo Pharmaceuticals is a biopharmaceutical company developing treatments for rare genetic mitochondrial diseases. This chart, which reflects market revenue estimates, is a measure of Reneo's hope. It shows how much investors value the company's potential to help patients with severe diseases for which there are no approved treatments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Reneo Pharmaceuticals
Reneo Pharmaceuticals is a clinical-stage biotech company focused on developing treatments for rare genetic mitochondrial diseases. This chart reflects investor hopes that its lead candidate will successfully complete clinical trials and become the first therapy for patients with these debilitating conditions.
%20P%2FS%20Reneo%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Reneo-Pharmaceuticals&v=1772658262654 "The graph of the company's future (projected) P/S Reneo Pharmaceuticals")
Future (projected) P/S of the market segment - Specialized pharma
Reneo Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to treat rare genetic mitochondrial diseases. This chart reflects average revenue expectations in the biotech sector. It helps assess how highly the market values Reneo's potential to treat rare diseases.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772658262668 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Reneo Pharmaceuticals is a biopharmaceutical company developing treatments for rare genetic mitochondrial diseases. This indicator reflects collective market expectations. The company's success in developing therapies for these debilitating conditions could not only transform patients' lives but also open a new market in the pharmaceutical industry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772658262677 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Reneo Pharmaceuticals
This chart shows the revenue of Reneo Pharmaceuticals, a clinical-stage biopharmaceutical company developing drugs to treat rare genetic diseases. Its revenue, if any, comes from collaboration fees with other companies, reflecting research progress rather than sales.
Sales of companies in the market segment - Specialized pharma
Reneo Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare genetic mitochondrial diseases. This graph shows the potential market for orphan drugs. Reneo's success in this complex area could not only offer treatment for patients with no other options but also create an entirely new therapeutic niche.
Overall market sales
Reneo Pharmaceuticals is a biopharmaceutical company focused on treating rare genetic diseases. Its prospects depend on the success of clinical trials. The overall economic situation, shown in this chart, affects the availability of capital for funding long-term biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Reneo Pharmaceuticals
Reneo Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare genetic diseases related to energy metabolism. Future revenue is dependent on the success of clinical trials. The chart reflects expectations for the orphan drug market.
%20sales%20of%20the%20company%20Reneo%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Reneo-Pharmaceuticals&v=1772658262692 "Schedule of future (projected) sales of the company Reneo Pharmaceuticals")
Future (projected) sales of companies in the market segment - Specialized pharma
Reneo Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare genetic mitochondrial diseases that disrupt cellular energy metabolism. This chart shows the forecast for the entire orphan drug market, where Reneo aims to offer therapy to patients with no other treatment options.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772658262697 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Reneo Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to treat rare genetic mitochondrial diseases. Its valuation is dependent on the success of clinical trials. This graph, reflecting investor sentiment, influences the availability of capital for funding orphan disease research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772658262706 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Reneo Pharmaceuticals
Reneo Pharmaceuticals is a biotech company developing drugs to treat rare genetic diseases associated with mitochondria. Being in the clinical stage, it incurs significant R&D expenses. This chart shows its net losses—investments in developing drugs for patients with extremely rare and severe diseases.
Market segment marginality - Specialized pharma
Reneo Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in the development of treatments for rare genetic mitochondrial diseases. Profitability is a long-term goal. This chart reflects clinical trial costs. Investors evaluate it in the context of the potential for benefiting patients with severe diseases.
Market marginality as a whole
Reneo Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare genetic mitochondrial diseases that affect cellular energy production. This overall profitability curve is irrelevant to them. Their future depends solely on the success of their clinical programs and their ability to bring a drug to market for patients with rare diseases.
Employees in the company, segment and market as a whole
Number of employees in the company Reneo Pharmaceuticals
Reneo Pharmaceuticals is a clinical-stage biotech company developing therapeutics for rare genetic diseases. It operates with a small team of experts. This chart reflects its lean, R&D-focused model, with many functions outsourced.
Share of the company's employees Reneo Pharmaceuticals within the market segment - Specialized pharma
Reneo Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare genetic mitochondrial diseases. This chart shows its share of the total number of researchers in this niche area. It is an indicator of the scale of its clinical programs and the size of the scientific team working on developing life-saving drugs.
Number of employees in the market segment - Specialized pharma
Reneo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic mitochondrial diseases. This chart shows the dynamics of employment in the orphan drug sector. The growing number of scientists reflects progress in clinical trials and the hope of developing therapies for patients with severe diseases.
Number of employees in the market as a whole
Reneo Pharmaceuticals is a biotechnology company developing drugs to treat rare genetic diseases. Its development requires significant investment in clinical research. Overall economic stability, illustrated by this chart, impacts the availability of capital to finance long-term and risky R&D projects.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Reneo Pharmaceuticals (RPHM)
Reneo Pharmaceuticals is a biotech company developing drugs to treat rare genetic diseases related to metabolism. This is pure R&D. The chart shows that the company's market value is based solely on the potential of its drug candidates. The high market capitalization per employee reflects the market's value of the team's intellectual capital and their patents.
%20of%20the%20company%20Reneo%20Pharmaceuticals%20(RPHM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Reneo-Pharmaceuticals-RPHM&v=1772658262732 "Chart of market capitalization per employee (in thousands of dollars) of the company Reneo Pharmaceuticals (RPHM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Reneo Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare genetic mitochondrial diseases. Its value is determined by the potential of its clinical programs. This chart demonstrates the high market valuation of its research assets and prospects based on its small team of scientists.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772658262736 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Reneo Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to treat rare genetic diseases. The chart shows the company's scientific potential. It reflects how the market views their pipeline, where the contribution of a small team of scientists can lead to the creation of a sought-after drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772658262739 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Reneo Pharmaceuticals (RPHM)
Reneo Pharmaceuticals is a clinical-stage biotech company specializing in developing drugs to treat rare metabolic and muscular diseases. This is R&D. This chart shows capital burn: the amount the company spends on each scientist during expensive clinical trials.
%20Chart%20Reneo%20Pharmaceuticals%20(RPHM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Reneo-Pharmaceuticals-RPHM&v=1772658262742 "Company Profit Per Employee (in thousands of dollars) Chart Reneo Pharmaceuticals (RPHM)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Reneo Pharmaceuticals is a clinical-stage biotechnology company developing drugs to treat rare genetic mitochondrial diseases. This metric (loss per employee) reflects the high costs of R&D and clinical trials.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772658262745 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Reneo Pharmaceuticals (RPHM) is a clinical-stage biotech company specializing in the treatment of rare metabolic diseases. It is an R&D company and is not profitable. This chart shows the company's capital burn rate: operating loss per research team.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772658262763 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Reneo Pharmaceuticals (RPHM)
Reneo Pharmaceuticals is a biopharmaceutical company developing treatments for rare genetic mitochondrial diseases. This chart reflects the progress of its research commercialization. Revenue growth at this stage will depend on the success of clinical trials and potential partnerships.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Reneo-Pharmaceuticals-RPHM&v=1772658262769 "Sales chart per company employee Reneo Pharmaceuticals (RPHM)")
Sales per employee in the market segment - Specialized pharma
Reneo Pharmaceuticals (RPHM) is a biotech company focused on developing treatments for rare genetic metabolic diseases. While in the clinical stage, their revenue (if any) comes from partnerships. This chart shows how productive their R&D team is in monetizing their developments per scientist.
Sales per employee for the market as a whole
Reneo Pharmaceuticals (RPHM) is a clinical-stage biotechnology company specializing in drugs for the treatment of rare genetic mitochondrial diseases. The company has no commercial revenue yet. This chart illustrates a typical R&D situation: an entire staff of scientists is working on developing future drugs, consuming investment capital.
Short shares by company, segment and market as a whole
Shares shorted by company Reneo Pharmaceuticals (RPHM)
Reneo Pharmaceuticals is a biotech company developing drugs to treat rare metabolic diseases. The bearish sentiment shown in this chart is a classic bet against biotech: investors don't believe its drug candidates will successfully pass clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Reneo-Pharmaceuticals-RPHM&v=1772658262826 "Short Shares Chart for the Company Reneo Pharmaceuticals (RPHM)")
Shares shorted by market segment - Specialized pharma
This chart reflects the general investor skepticism toward biotech companies developing drugs for rare diseases. Reneo Pharmaceuticals focuses on genetic myopathies. The high short interest in the sector suggests investors are unsure of the success of clinical trials or the commercial potential of highly targeted drugs.
Shares shorted by the overall market
Reneo is a biotech company working on rare metabolic diseases. It's a classic R&D story. This chart measures the overall level of fear in the market. When it's high, investors are unwilling to fund multi-year clinical trials. They see "another unprofitable company" and sell, fearing the cash will run out.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Reneo Pharmaceuticals (RPHM)
Reneo Pharmaceuticals (RPHM) is a biotech company developing drugs to treat rare genetic diseases related to metabolism. This chart tracks how investors view its clinical data, showing it as "overheated" (above 70) on positive news or "oversold" (below 30) on delays or setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Reneo-Pharmaceuticals-RPHM&v=1772658262837 "RSI 14 indicator chart for the company's stock Reneo Pharmaceuticals (RPHM)")
RSI 14 Market Segment - Specialized pharma
Reneo Pharmaceuticals is a clinical-stage biotech company focused on treating rare genetic mitochondrial diseases that cause muscle weakness. This chart reflects the overall sentiment in the biotech sector, helping to gauge how the market views this speculative industry.
RSI 14 for the overall market
Reneo (RPHM) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RPHM (Reneo Pharmaceuticals)
Reneo (RPHM) is a clinical-stage biotech company specializing in the treatment of rare genetic diseases associated with metabolism and muscle function. This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of its scientific platform and their expectations for data from key clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RPHM-Reneo-Pharmaceuticals&v=1772658262851 "A chart showing analyst consensus forecasts for the expected stock price. RPHM (Reneo Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price RPHM (Reneo Pharmaceuticals)
Reneo (RPHM) is a biotech company developing drugs to treat rare metabolic and muscle diseases. This chart shows the difference between the market valuation and the consensus forecast. It highlights the potential (and risks) analysts see in their R&D portfolio and the chances of clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RPHM-Reneo-Pharmaceuticals&v=1772658262855 "A chart showing the difference between the consensus forecast and the actual stock price. RPHM (Reneo Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Reneo Pharma is a biotech focused on cellular energy. The company develops drugs to treat rare metabolic diseases associated with mitochondria. This chart displays analyst expectations for the *entire* specialty pharma sector. It shows whether experts believe this R&D approach will be successful.
Analysts' consensus forecast for the overall market share price
Reneo Pharmaceuticals (RPHM) is a clinical-stage biopharmaceutical company focused on treating rare genetic diseases (metabolism, muscle). This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It is an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Reneo Pharmaceuticals
Reneo is a biotech mitochondria hunter. It's an R&D company developing small molecules (MAVAdri-gal) to activate mitochondria (the cell's powerhouse) for the treatment of rare genetic diseases. This graph is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Specialized pharma
Reneo Pharmaceuticals (RPHM) is a specialty pharmaceutical company. They develop drugs for ultra-rare genetic metabolic diseases for which there are no cures. This chart compares their composite index to the sector, showing how their R&D in rare diseases compares to others.
The AKIM Index for the overall market
Reneo Pharmaceuticals, a company developing drugs for mitochondrial diseases, merged with OnKure Therapeutics. This chart, which reflects the market average, provides a macro backdrop. It helps assess how the company, as it undergoes transformation, compares to overall economic trends.
